TB-500, and copper peptide to build muscle, rejuvenate skin, and boost longevity. But do they work and are they safe?

The MarketWatch News Department was not involved in the creation of this content. SAN DIEGO, Nov. 18, 2025 /PRNewswire/ --Neurogan Health, a brand known for clean, science-driven innovation, today has ...

Early adopters are already seeing results: "I used to struggle with scalp irritation, and this serum has definitely improved my scalp health. It also feels like my hair is growing faster." "I've tried ...

GHK-Cu: Supports tissue repair, collagen production, and scalp wellness. AHK-Cu: Stimulates follicle elongation, promotes dermal papilla cell activity, and helps keep hair in the growth (anagen) phase ...

Enable Injections, maker of the enFuse wearable drug delivery system, inked a partnership deal with Incyte to join the companies' technologies in a bid to advance patient care in certain diseases. The ...

The Boston City Council struck down a resolution opposing safe injection sites, with proponents rejecting notions that legalizing such centers would incentivize addicts to shoot up and saying that ...

City Councilor Ed Flynn is calling for the Council to oppose safe injection sites in Boston that he says would incentivize addicts to shoot up, rather than seek treatment, and worsen the open-air drug ...

New York City residents are speaking out after users at a taxpayer-funded "safe injection site" operated by OnPoint have left their neighborhood rife with social dysfunction – including public ...

GREENWICH, Conn.--(BUSINESS WIRE)--GHK Capital Partners LP (“GHK”), a leading middle-market private equity firm, announced today that it has completed the acquisition of Rogers Building Solutions ...

Two city-approved “safe” drug injection sites could be forced to close under a new executive order issued by President Trump, which rips the facilities, where addicts can use illegal drugs like meth, ...

Doctors at DAP Health have begun administering a new twice-a-year injectable HIV prevention medication, which was approved by the Food and Drug Administration in June. Gilead's drug lenacapavir ...

Venture Partners at CU Boulder has announced the first recipients of a new translational funding program designed to advance promising, early-stage therapeutics with strong commercial potential. The ...